Drugs / Carlumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01204996 | May 2010 → Nov 2011 | cancer | Centocor, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00537368 | Sep 2007 → Mar 2010 | cancer | Centocor, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT00992186 | Sep 2009 → Jul 2011 | prostate cancer | Centocor Research & Development, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00786201 | Dec 2008 → Jan 2012 | pulmonary fibrosis | Centocor, Inc. | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carlumab | “Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors” PMID 24928772 ↗ Jun 2014 |
| Known as | CNTO 888 | “CNTO 888 is an antibody that works by blocking a protein called CC-chemokine ligand 2 (CCL2).” NCT01204996 ↗ |
| Action | Inhibit | “CNTO 888 is thought to work by blocking a protein called CC-Chemokine Ligand 2 (CCL2).” NCT00537368 ↗ |
| Modality | Monoclonal antibody | “CNTO 888 is a monoclonal antibody.” NCT00537368 ↗ |
| Route | Intravenous | “CNTO 888 is given by intravenous (into the vein) infusion.” NCT00537368 ↗ |
| Target | CCL2 | “CNTO 888 is thought to work by blocking a protein called CC-Chemokine Ligand 2 (CCL2).” NCT00537368 ↗ |